NCT06065176View on ClinicalTrials.gov

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

1,188

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

September 2, 2024

Study Completion Date

September 9, 2024

Conditions
COVID-19Vaccine-Preventable DiseasesSARS CoV 2 InfectionUpper Respiratory Tract InfectionUpper Respiratory Disease
Interventions
BIOLOGICAL

Novavax COVID-19 vaccine (2023-2024 formula XBB containing)

Participants will receive a single dose of the Novavax vaccine.

BIOLOGICAL

Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)

Participants will receive a single dose of the Pfizer vaccine.

Trial Locations (1)

84108

University of Utah School of Medicine, Salt Lake City

Sponsors

Collaborators (2)

Westat
Novavax
All Listed Sponsors
collaborator

Westat

OTHER

collaborator

Novavax

INDUSTRY

lead

Sarang K. Yoon, DO, MOH

OTHER